Personal profile
Education/Academic qualification
PhD, University College London
24 Mar 2014 → 28 Jul 2017
Award Date: 28 Jul 2017
External positions
Postdoctoral Research Fellow, Stanford University Cancer Institute, Stanford, United States
1 Sept 2022 → 1 Oct 2025
Fingerprint
Dive into the research topics where Anne Marijn Kramer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Ghorashian, S., Kramer, A. M., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S. J., Casanovas-Company, J., Castro, F., Popova, B., Villanueva, K., Yeung, J., Vetharoy, W., Guvenel, A., Wawrzyniecka, P. A., Mekkaoui, L., Cheung, G. W. K., Pinner, D., Chu, J. & Lucchini, G. & 24 others, , 1 Sept 2019, In: Nature medicine. 25, 9, p. 1408-1414 7 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile81 Downloads (Pure) -
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
CARdinal-22 Investigator group, 27 Jul 2024, In: Lancet. 404, 10450, p. 353-363 11 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile54 Downloads (Pure) -
Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen–Directed CAR T-Cell Therapy
Kuipers, M. T., Migchelbrink, J., Kramer, A. M., Kouwenhoven, M. C. M., Zweegman, S., Groen, K. & van de Donk, N. W. C. J., 2026, (E-pub ahead of print) In: BioDrugs.Research output: Contribution to journal › Review article › Academic › peer-review
Open Access -
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Su, Y.-J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, S., Chinnasamy, H., Gkitsas-Long, N., Klysz, D. D., Brown, A. K., Bharadwaj, S., Dahiya, S. & Smith, M. & 6 others, , 1 Apr 2025, In: Cancer discovery. 15, 4, p. 733-747 15 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Dreyzin, A., Kramer, A. M., Yates, B., Wang, H.-W., Sahaf, B., Yuan, C., Klysz, D., Tunuguntla, R., Ehlinger, Z., Reitberg, S., Adebola, S., Su, A., Ebina-Shibuya, R., Jia, D., Achar, S., Patil, S., Martin, K., Jeyakumar, N., Davis, K. L. & Fry, T. & 13 others, , 2025, (E-pub ahead of print) In: Cytotherapy. 101990.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile77 Downloads (Pure)
Activities
- 1 Invited talk
-
Optimizing Long Term Outcome of patients with B-cell lymphomas
Kramer, A. M. (Speaker)
2025Activity: Talk or presentation › Invited talk › Academic